 Pharmacogenomic Testing
"Pharmacogenomic Testing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The detection of genetic variability (e.g., PHARMACOGENOMIC VARIANTS) relevant to PHARMACOGENETICS and PRECISION MEDICINE. The purpose of such genetic testing is to help determine the most effective treatment options and their optimum dosages with least potential risks for DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS.
| Descriptor ID |
D000071185
|
| MeSH Number(s) |
E01.370.225.562.500 E05.200.562.500 E05.393.435.500 N02.421.308.430.500 N02.421.726.233.221.500
|
| Concept/Terms |
Pharmacogenomic Testing- Pharmacogenomic Testing
- Pharmacogenomic Testings
- Pharmacogenomic Screening
- Pharmacogenomic Screenings
- Pharmacogenetic Screening
- Pharmacogenetic Screenings
- Pharmacogenetic Testing
- Pharmacogenetic Testings
Pharmacogenomic Analysis- Pharmacogenomic Analysis
- Pharmacogenomic Analyses
- Pharmacogenetic Study
- Pharmacogenetic Studies
- Studies, Pharmacogenetic
- Pharmacogenetic Analysis
- Pharmacogenetic Analyses
- Pharmacogenomic Study
- Pharmacogenomic Studies
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Testing".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Testing".
This graph shows the total number of publications written about "Pharmacogenomic Testing" by people in this website by year, and whether "Pharmacogenomic Testing" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 0 | 1 | 1 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 1 | 2 | | 2019 | 1 | 2 | 3 | | 2020 | 3 | 2 | 5 | | 2021 | 3 | 3 | 6 | | 2022 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacogenomic Testing" by people in Profiles.
-
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022 07 12; 328(2):151-161.
-
Anderson HD, Thant TM, Kao DP, Crooks KR, Mendola ND, Aquilante CL. Pharmacogenetic testing among patients with depression in a US managed care population. Clin Transl Sci. 2022 Jul; 15(7):1644-1653.
-
Martin JL, Lee YM, Corbin LW, Colson R, Aquilante CL. Patients' perspectives of a pharmacist-provided clinical pharmacogenomics service. Pharmacogenomics. 2022 06; 23(8):463-474.
-
Ortega VE, Daya M, Szefler SJ, Bleecker ER, Chinchilli VM, Phipatanakul W, Mauger D, Martinez FD, Herrera-Luis E, Pino-Yanes M, Hawkins GA, Ampleford EJ, Kunselman SJ, Cox C, Bacharier LB, Cabana MD, Cardet JC, Castro M, Denlinger LC, Eng C, Fitzpatrick AM, Holguin F, Hu D, Jackson DJ, Jarjour N, Kraft M, Krishnan JA, Lazarus SC, Lemanske RF, Lima JJ, Lugogo N, Mak A, Moore WC, Naureckas ET, Peters SP, Pongracic JA, Sajuthi SP, Seibold MA, Smith LJ, Solway J, Sorkness CA, Wenzel S, White SR, Burchard EG, Barnes K, Meyers DA, Israel E, Wechsler ME. Pharmacogenetic studies of long-acting beta agonist and inhaled corticosteroid responsiveness in randomised controlled trials of individuals of African descent with asthma. Lancet Child Adolesc Health. 2021 12; 5(12):862-872.
-
Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021 12; 23(12):2335-2341.
-
Oreschak K, Saba LM, Rafaels N, Ambardekar AV, Deininger KM, PageII R, Lindenfeld J, Aquilante CL. Variants in mycophenolate and CMV antiviral drug pharmacokinetic and pharmacodynamic genes and leukopenia in heart transplant recipients. J Heart Lung Transplant. 2021 09; 40(9):917-925.
-
Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021 07; 110(1):179-188.
-
Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, Dunnenberger HM, Leeder JS, Callaghan JT, Samer CF, Klein TE, Haidar CE, Van Driest SL, Ruano G, Sangkuhl K, Cavallari LH, Müller DJ, Prows CA, Nagy M, Somogyi AA, Skaar TC. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021 10; 110(4):888-896.
-
Fohner AE, Dalton R, Skagen K, Jackson K, Claw KG, Hopkins SE, Robinson R, Khan BA, Prasad B, Schuetz EG, Nickerson DA, Thornton TA, Dillard DA, Boyer BB, Thummel KE, Woodahl EL. Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function. Clin Transl Sci. 2021 07; 14(4):1292-1302.
-
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 12 01; 3(12):e2029411.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|